MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 01-31-2026
Autolus Therapeutics plc Cash and Cash Equivalents 2011-2026 | AUTL
Annual Cash and Cash Equivalents Autolus Therapeutics plc
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 240 M | 382 M | 310 M | 153 M | 211 M | 217 M | 137 M | 28.1 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 382 M | 28.1 M | 210 M |
Quarterly Cash and Cash Equivalents Autolus Therapeutics plc
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 86.1 M | 124 M | 95.8 M | 657 M | 706 M | 759 M | 256 M | 308 M | 343 M | - | 163 M | - | - | 310 M | - | - | 239 M | 153 M | 178 M | 212 M | 243 M | 211 M | 229 M | 266 M | 188 M | 217 M | 247 M | 265 M | - | 129 M | 137 M | - | - | - | 28.1 M | - | - | - | 10.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 759 M | 10.2 M | 250 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M |  USA |
 |
Amgen
AMGN
|
12 B | $ 341.88 | - | $ 184 B | USA |
 |
ANI Pharmaceuticals
ANIP
|
145 M | $ 81.85 | -0.18 % | $ 1.58 B | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
227 M | $ 69.33 | - | $ 9.27 B | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Aytu BioScience
AYTU
|
31 M | $ 2.6 | - | $ 16.3 M | USA |
 |
Adagene
ADAG
|
75.2 M | $ 2.75 | -5.5 % | $ 155 M | China |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Alterity Therapeutics Limited
ATHE
|
34.8 M | $ 3.17 | -2.76 % | $ 7.63 B |  Australia |
 |
Biogen
BIIB
|
2.38 B | $ 179.89 | - | $ 26.2 B | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Aptose Biosciences
APTO
|
6.15 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Aeglea BioTherapeutics
AGLE
|
89.4 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
42.9 M | $ 1.41 | - | $ 264 M | USA |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
30 M | - | 3.16 % | $ 1.9 M | USA |
 |
Ascendis Pharma A/S
ASND
|
560 M | $ 226.1 | 0.96 % | $ 5 B |  Danmark |
 |
Ampio Pharmaceuticals
AMPE
|
4.09 M | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
61.1 M | - | - | $ 10.1 M | USA |
 |
BioNTech SE
BNTX
|
9.76 B | $ 113.75 | - | $ 27.2 B | Germany |
 |
Aravive
ARAV
|
53.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Athira Pharma
ATHA
|
48.4 M | - | - | $ 269 M | USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | USA |
 |
AVROBIO
AVRO
|
98 M | - | 1083.1 % | $ 745 M | USA |
 |
Burford Capital Limited
BUR
|
322 M | $ 9.69 | - | $ 1.54 B | Britain |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
144 M | - | -15.15 % | $ 60.3 M | Britain |
 |
Brickell Biotech
BBI
|
10.9 M | - | -5.38 % | $ 6.06 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
111 M | $ 13.68 | - | $ 4.23 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
8.27 M | $ 4.01 | -2.2 % | $ 8.73 B |  Israel |
 |
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | USA |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
105 M | $ 6.58 | -1.35 % | $ 1.36 B | USA |
 |
Alpine Immune Sciences
ALPN
|
13.4 M | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
118 M | - | 4.14 % | $ 49.1 M | USA |
 |
Beam Therapeutics
BEAM
|
282 M | $ 27.62 | - | $ 2.27 B | USA |
 |
BeiGene, Ltd.
BGNE
|
2.63 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | Israel |
 |
AstraZeneca PLC
AZN
|
5.49 B | $ 92.77 | 0.19 % | $ 96.9 B | Britain |